Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Announces AVANCE™-IVDr as a Standardized NMR Platform for Clinical Screening

Published: Tuesday, July 23, 2013
Last Updated: Tuesday, July 23, 2013
Bookmark and Share
New AVANCE-IVDr system offers high performance and throughput for the development and validation of emerging high-quality, information-rich and cost-effective IVD-by-NMR and clinical screening assays.

Bruker has announced a standardized nuclear magnetic resonance (NMR) spectroscopy platform for its clinical and diagnostics partners that enables cost-effective, high-performance NMR clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays.

The new AVANCE-IVDr system, presently for research use only, is a complete, proven and standardized platform for NMR clinical research and screening, as well as for IVD-by-NMR research.

It features high sensitivity and information-rich output at 600 MHz proton-NMR frequency, and incorporates advanced hardware, software, automation, spectral libraries and standard operating procedures (SOPs) for high-performance bio-fluid screening and assay validation.

Customer benefits include higher information content and spectral feature differentiation compared to low-field NMR systems, as well as excellent reproducibility, high throughput and potentially dramatically lower cost per sample for better clinical screening and IVD-by-NMR.

Dedicated to NMR-based clinical screening and diagnostics, the AVANCE-IVDr is optimized for ease-of-use and highest data quality and reliability.

The new standardized platform offers barcode analysis, control by a LIMS system, the high-throughput, temperature-controlled autosampler SampleJet™, remote access, and automatic analysis and customizable analytical results reporting.

Based on Bruker-validated SOPs, the AVANCE-IVDr platform enables the development of diagnostic tools for body-fluids, or even biopsy samples, that can address a variety of medical questions.

The SOPs guarantee the production of highly reproducible clinical data, enabling the exchange and validation of novel NMR assays between laboratories on a global basis.

In a translational clinical research environment the results produced by these NMR assays can easily be transferred into clinical screening and future IVD use.

Bruker's NMR spectroscopy systems are already in use in more than forty clinical research centers worldwide, including hospitals working on modern health-related screening techniques, such as human metabonomics.

The AVANCE-IVDr system in its latest, standardized configuration has been installed already at several customer and strategic partner sites.

Cross calibrations performed by Bruker across several centers have demonstrated NMR's unique advantage that spectra from samples prepared and measured under the Bruker SOPs are identical, independent of a center's location or operating staff.

As a result of a long-standing collaboration with Imperial College London, the AVANCE-IVDr platform is already enabling the analysis of over 100,000 samples per year at the UK's recently opened MRC-NIHR Phenome Centre. This level of large-scale health-related NMR screening is paving the way for worldwide epidemiological studies as well as for clinical research and diagnosis.

The benefits have been significant: facilitated by the low cost per sample and the even lower cost per parameter as compared to established single parameter screening methods, novel NMR methods for determining the cause of disease, delivering individualized patient treatment and developing strategies for prevention are now available to many clinical researchers.

Professor Jeremy Nicholson, Director of the MRC-NIHR Phenome Centre and Head of the Department of Surgery and Cancer at Imperial College London, commented: "The latest generation of Bruker NMR instruments gives us staggering day to day and long term reproducibility and reliability of spectral acquisition, coupled with the ability to do automated digital quantification of multiple metabolites. Thus, uniquely, the NMR technology platform can be used in simultaneous exploratory and targeted modes. We are totally committed to the use of NMR spectroscopy (in association with mass spectrometry) as a definitive bio-screening tool, and the latest technology developments now allow the deployment of the platform on an industrial scale."

Dr. Manfred Spraul, Bruker's Director of Applied NMR Business Development, added: "Migrating from translational research to clinical diagnostics requires robust, identical instrumentation in research facilities and hospitals, which is why Bruker has decided to offer the standardized AVANCE-IVDr platform, enabling a smooth transfer from health research and large epidemiological studies, to our partners' emerging IVD assays at the highest quality and reproducibility. With modern NMR technology and the right SOPs, we and our collaborators have opened the path to complex mixture analysis using push-button technology, establishing NMR as one of the two major technologies used in metabolic profiling and screening."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Full Range of Bruker Systems Installed in New Pre-Clinical Imaging Laboratory
Researchers, clinicians, health educators and policy makers all gathered as the new Multidisciplinary Centre for Research into Obesity and Related Comorbidities (Cepid-OCRC) was opened at da Universidade Estadual de Campinas (UNICAMP).
Thursday, June 18, 2015
UK National Graphene Institute Selects Bruker as Official Partner
World-leading graphene research facility purchases multiple Bruker AFMs.
Tuesday, April 07, 2015
PREMIER Biosoft Announces Reseller Agreement with Bruker
Agreement aims to advance lipidomics and metabolomics research.
Monday, November 17, 2014
Bruker Sells GC Business
Bruker completed the divestiture of its GC and GC single-quadrupole (GC-SQ) mass spectrometry products to Techcomp Europe Ltd on October 31st.
Tuesday, November 04, 2014
Bruker Awarded Fourth PeakForce Tapping Patent
AFM mode uniquely combines highest resolution imaging and material property mapping.
Thursday, July 24, 2014
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
Tuesday, July 22, 2014
Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker Opens New Preclinical Imaging Center of Excellence for the Americas
Massachusetts Center will provide advanced development, demonstration and customer support capabilities for Bracer’s unique multimodal preclinical imaging systems portfolio.
Thursday, January 30, 2014
Bruker Corporation Appoints Dr. Gilles Martin to its Board of Directors
Dr. Martin is Chairman and Chief Executive Officer of the Eurofins Scientific Group.
Monday, January 20, 2014
World’s First Compact 900 MHz Actively Refrigerated Magnet for NMR Installed at UCSD
Bruker announce the successful installation of an Ascend™ Aeon 900 magnet, the world’s first compact, single-story NMR magnet with active refrigeration.
Wednesday, December 11, 2013
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.
Tuesday, November 26, 2013
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker Announces Acquisition of Prairie Technologies
Acquisition strengthens Bruker Nano Surfaces Division's position in life science markets.
Friday, September 13, 2013
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!